HER2 Positive Breast Cancers Recruiting Phase 2 Trials for Lapatinib (DB01259)

Also known as: HER2 Positive Breast Cancer

IndicationStatusPhase
DBCOND0066412 (HER2 Positive Breast Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02362958A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast CancerTreatment